ストックスクリーナーアプリを入手
1.42
0.70%
0.00
前日終値:
$1.42
開ける：
$1.4
24時間の取引高:
6,601
Relative Volume:
0.01
時価総額：
$4.11M
収益：
$142.00K
当期純損益:
$-1.23M
株価収益率:
3.0492
EPS:
0.4657
ネットキャッシュフロー:
$-10.62M
1週間 パフォーマンス:
-0.69%
1か月 パフォーマンス:
-16.37%
6か月 パフォーマンス:
-34.70%
1年 パフォーマンス:
-25.52%
1日の値動き範囲:
$1.40
$1.48
1週間の範囲:
$1.38
$1.5492
52週間の値動き範囲:
$1.25
$5.30
Vivosim Labs Inc Stock (VIVS) Company Profile
Compare VIVS vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VIVS
Vivosim Labs Inc
|
1.42 | 4.11M | 142.00K | -1.23M | -10.62M | 0.4657 |
VRTX
Vertex Pharmaceuticals Inc
|
428.19 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
719.55 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
812.78 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.61 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.16 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Vivosim Labs Inc Stock (VIVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2018-12-13 | 開始されました | H.C. Wainwright | Buy |
| 2017-11-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 開始されました | Raymond James | Outperform |
| 2015-08-11 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 開始されました | Jefferies | Buy |
| 2015-06-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Vivosim Labs Inc (VIVS) 最新ニュース
What VivoSim Labs (VIVS) capital allocation tells us | Q3 2025: Better Than ExpectedGuidance Update - Newser
Can AI replace animal tests? VivoSim cites 96% diarrhea accuracy - Stock Titan
VIVS Price Today: VivoSim Labs, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
VIVS VivoSim Labs notches 32.1 percent Q3 2025 revenue growth, shares edge higher on narrower than expected loss.AI Stock Signals - Newser
VivoSim Labs (VIVS) Stock: Is It a Compelling Buy (-4.35%) 2026-04-20Earnings Beat Stocks - Cổng thông tin điện tử Tỉnh Sơn La
VIVS Technical Analysis & ETF Price Forecast - Intellectia AI
Gap Down: Will VivoSim Labs Inc benefit from AI trendsEarnings Trend Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Esousa Group reports 9.9% stake in VivoSim Labs (NASDAQ: VIVS) - Stock Titan
VIVS SEC FilingsVivoSim Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
VivoSim Labs Announces $4 Million Public Offering to Accelerate Adoption of 3D Human Tissue Models for Drug Testing - Minichart
VivoSim Labs Prices Best-Efforts Public Offering - TipRanks
VivoSim Labs Raises ~$2.5M in Initial Tranche; Signs Purchase and Placement Agreements - TradingView
VivoSim Labs (Nasdaq: VIVS) raises $3M in first tranche of $4M deal - Stock Titan
VivoSim Labs (NASDAQ: VIVS) registers 3.51M shares with detachable warrants - Stock Titan
VivoSim Announces Pricing of up to a $4 Million Public Offering - Sahm
VivoSim Labs prices $4 million public offering at $1.14/share By Investing.com - Investing.com Australia
VivoSim Labs prices $4M public offering at $1.14 per share - Investing.com Australia
VivoSim Labs, Inc. (VIVS) stock price, news, quote and history - au.finance.yahoo.com
VIVS Stock Analysis: VivoSim Labs Inc gains 13.68 percent to 1.62 amid bullish momentum - Cổng thông tin điện tử Tỉnh Sơn La
[EFFECT] VivoSim Labs, INC. SEC Filing - Stock Titan
VivoSim Labs (NASDAQ: VIVS) outlines $4M two-tranche stock and warrant financing - Stock Titan
Aug Breakouts: Is VivoSim Labs Inc benefiting from innovation trendsWeekly Gains Summary & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-29 07:44:35 - baoquankhu1.vn
VivoSim Labs (NASDAQ: VIVS) files S-1 for $4M unit offering - Stock Titan
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing - GlobeNewswire
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs - Yahoo Finance
VivoSim Labs, Inc.: Fundamental Analysis and Financial Ratings | 4OR | US68620A3023 - marketscreener.com
Market Catalysts: What is the cash position of VivoSim Labs Inc2026 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Is VivoSim Labs Inc. stock a buy before product launchesJuly 2025 Rallies & Safe Capital Investment Plans - Naître et grandir
Buyback Watch: How much upside does VivoSim Labs Inc haveTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Why Is VIVS Stock Up 79% Today? - Stocktwits
VIVS Earnings History & Surprises | EPS & Revenue Results | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim names Raghunathan as VP of global sales By Investing.com - Investing.com Canada
VivoSim names Raghunathan as VP of global sales - Investing.com Nigeria
Vivosim appoints Arumugham (Ragoo) Raghunathan as vice president of global sales - marketscreener.com
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewswire
VIVS Should I Buy - Intellectia AI
VIVS Technical Analysis & Stock Price Forecast - Intellectia AI
Exit Recap: Is VivoSim Labs Inc showing insider buying2025 Trading Volume Trends & Weekly Chart Analysis and Guides - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Travel Stocks: Does VivoSim Labs Inc have pricing powerJuly 2025 Patterns & Long-Term Capital Growth Ideas - baoquankhu1.vn
Rate Cut: Is VivoSim Labs Inc showing insider buyingQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Sectors Review: Is SmartKem Inc part of any ETFTrade Performance Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Is VivoSim Labs Inc. benefiting from innovation trends2025 EndofYear Setup & Precise Buy Zone Identification - mfd.ru
Why VivoSim Labs Inc. stock is rated strong buyJuly 2025 Review & Risk Controlled Daily Plans - mfd.ru
VIVS Financials: Income Statement, Balance Sheet & Cash Flow | VivoSim Labs Inc - Stock Titan
Aug Fed Impact: Is LXFRs ROE strong enough2025 Market Sentiment & Stock Market Timing Techniques - baoquankhu1.vn
VIVS Income Statement | VIVOSIM LABS INC (NASDAQ:VIVS) - ChartMill
VivoSim (VIVS) to Present Innovative Data at SOT Meeting - GuruFocus
VivoSim to Debut Antibody Drug Conjugate Data, representing - GlobeNewswire
Shorts Report: Is VivoSim Labs Inc a stock for growth or value investors2025 Big Picture & Low Drawdown Trading Techniques - baoquankhu1.vn
Vivosim Labs Inc (VIVS) 財務データ
収益
当期純利益
現金流量
EPS
0.78%
3.01%
大文字化:
|
ボリューム (24 時間):